MRNA-4157 is under clinical development by Moderna and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRNA-4157’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRNA-4157 overview
mRNA-4157 is under development for the treatment of solid tumors including, melanoma, metastatic melanoma, non-small cell lung cancer, squamous non-small cell lung cancer, locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC), small-cell lung cancer, head and neck squamous cell carcinoma, bladder urothelial carcinoma, head and neck squamous cell carcinoma including oral cavity cancer, laryngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, gastric/ gastroesophageal (GEJ) cancer, pancreatic ductal adenocarcinoma (PDAC), renal cell carcinoma and colorectal cancer. It is administered through intramuscular route. The therapeutic candidate is developed by using mRNA vaccine technology, which enables the delivery of mRNA encoding for peptides containing personalized neoantigens to specific tumors and LNP technology. It was also under development for the treatment of stomach adenocarcinoma, esophageal adenocarcinoma and endometrial cancer. It is a personalized cancer vaccine.
Moderna overview
Moderna is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-4157’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
